Tagged with BI

Taiwan Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US, following ten completed clinical studies. President Antony Hsu outlines the science behind selective adipocyte apoptosis, the regulatory strategy behind the…

Taiwan Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has positioned Fethiann as Taiwan’s sole specialist in natural phytochemical active pharmaceuticals. The company’s unique business model integrates Active Phytochemicals Ingredient…

USA Writing in the January 2026 edition of DIA Global Forum, Mariana Socal and Antonio J. Trujillo from the Johns Hopkins Bloomberg School of Public Health and Rachel Goode of Fresenius Kabi argue  that biosimilars could significantly reduce US drug spending and expand patient access, but that their impact is being…

Europe Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the medicines life cycle, while the pharma sector itself contributes materially to global emissions. Against this backdrop, the European Medicines Agency…

LatAm From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already considered global standards. According to the Waiting to Access Innovative Therapies (W.A.I.T.) Indicator from FIFARMA, an association representing research-based pharma…

USA Neil F. McFarlane, President and CEO of Zevra Therapeutics, reflects on how his experiences in clinical practice, military service, and leadership roles across biotech and mid-sized pharma come together and led him to this moment. Under McFarlane, Zevra is driven by the urgency of patient needs and engaging with patient…

USA Alberto Santagostino, CEO of AGC Biologics, discusses how the company is positioning itself in an increasingly regionalized CDMO market, the strategic value of its global manufacturing footprint, and the role of technical expertise and long-term partnerships in supporting advanced biologics and cell and gene therapy programs. Santagostino goes on to…

USA Loretta Beine, Senior Director of Industry Development for Life Sciences, Empire State Development (ESD) explains the organization’s broader role in growing New York State’s life sciences sector beyond direct funding. As New York State’s chief economic development agency, ESD focuses on supporting startups, attracting new investment, and job creation to…

LatAm Raphaël Chin-Fo-Sieeuw, Vice President Life Sciences and Healthcare Americas, DHL Group outlines the Americas as a core growth region, with strong momentum in Latin America. He details DHL’s multi-billion-Euro investment in cold chain infrastructure, digitalisation, talent, and sustainability to support advanced therapies, evolving supply chains, and increasingly complex logistics demands…

France Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new expectations of industry-public collaboration. In this interview, Marina Vasiliou reflects on how these forces are reshaping the affiliate’s mission, the…

USA Catherine Owen Adams, CEO of Acadia Pharmaceuticals, discusses how the company’s dual commercial pillars in Parkinson’s disease psychosis and Rett syndrome are delivering much-needed impact for patients with significant unmet needs and shaping Acadia’s next phase of growth. She shares insights into the company’s expansion plans, pipeline strategy, partnership goals,…

France Erick Lelouche has served as President of Lyonbiopôle since February 2025, bringing more than 35  years of experience in the pharmaceutical industry across Pfizer and Boehringer Ingelheim, spanning human and animal health in France, Germany, and the US. Together with General Manager Teddy Breyton, whose background lies in regional economic…